Tradestie Institutional Equity Comparison Engine

ANL vs TYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANL Overall Edge

ANL Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ANL (ANL) driven by superior Momentum & Technical, Options & Structure while TYRA counters with relative strength in Growth & Margin. Fundamentally, ANL trades at N/M Forward P/E with -123.5% operating margin (+178.1% YoY revenue) versus TYRA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TYRA sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANL N/M vs TYRA N/M Fwd P/E
Growth & Margin Winner TYRA
Op Margin -123.5% vs 0.0% ยท YoY +178.1% vs +0.0%
Momentum & Technical Winner ANL
1Y +560.3% vs +26.8% ยท 52W Pos 56% vs 20%
Options & Structure Winner ANL
UNCLASSIFIED (N/A IV) vs BREAKDOWN (3rd %ile IV)
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
1M Return -9.61%
1Y Return +560.26%
Forward P/E N/M
Unified AI Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap $1.3B
1M Return +6.75%
1Y Return +26.81%
Forward P/E N/M
Unified AI Score
33.0 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANL +560.26% TYRA +26.81% Spread: +533.45 pp (ANL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANL TTM Op. Margin: -123.5% TYRA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs TYRA. Trailing 12-month operating profitability (ANL -123.5% vs TYRA 0.0%) and valuation multiples (ANL N/M vs TYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANL (4) vs TYRA (4)
Institutional Metric ANL TYRA Criterion Row Winner
Market Capitalization Scale $677.5M $1.3B Larger Scale TYRA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +178.1% +0.0% Higher Growth ANL
Operating Margin (TTM) Profitability -123.5% 0.0% Higher Margin TYRA
Net Profit Margin Profitability -124.8% 0.0% Higher Margin TYRA
Return on Equity (ROE) Capital Efficiency -20.2% -34.9% Higher ROE ANL
52-Week Range Position Momentum 56% ($1โ€“$17) 20% ($15โ€“$41) Stronger Trend ANL
Beta / 30D Volatility Risk Regime 2.61ฮฒ ยท 79% Vol 0.79ฮฒ ยท 49% Vol Lower Realized Risk TYRA
Unified Institutional Score Composite Signal 48.3 / 100 (HOLD) 33.0 / 100 (SELL) Higher Composite ANL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANL vs TYRA Buy Guide
ANL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ANL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TYRA BREAKDOWN
76d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live TYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANL nor TYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.